A new treatment for severe malaria - Intravenous (IV) Artesunate – will be developed and commercialized under a collaborative research and development agreement between the Walter Reed Army Institute of Research (WRAIR), the U.S. Army Medical Materiel Development Activity (USAMMDA), and Sigma-Tau Pharmaceuticals Inc.
According to Colonel Peter J. Weina, MD, PhD, WRAIR:
"We saw a need for improved severe malaria treatment not only to protect our troops abroad, but as a potential treatment for those around the world affected by this devastating illness.
WRAIR's vast research network played an important role in helping us research this new treatment for severe malaria, and with Sigma-Tau's help we are hopeful that IV Artesunate will one day become available to people around the globe."
Sigma-Tau will complete the research studies and be responsible for the commercial development and manufacturing of IV Artesunate should the FDA approve it. Submission of the application for FDA review of IV Artesunate is targeted on 2008.
Find more details from the press release.
Comment Preview